Abstract The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the
need to develop effective therapies against the causative agent, SARS-CoV-2, and also …

Coronaviruses are responsible for a growing economic, social and mortality burden, as the
causative agent of diseases such as severe acute respiratory syndrome (SARS), Middle …

Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory
syndrome–coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2) that is causing …

Over the past 2 decades 2 previously unknown coronaviruses (CoVs), the severe acute
respiratory syndrome CoV (SARS-CoV) and the Middle East respiratory syndrome CoV …

The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires
an urgent deployment of advanced therapeutic options available. The role of …

Background Antivirals are needed to combat the COVID-19 pandemic, which is caused by
SARS-CoV-2. The clinically-proven protease inhibitor Camostat mesylate inhibits SARS …

The molecular pathology of multi-organ injuries in COVID-19 patients remains unclear,
preventing effective therapeutics development. Here, we report a proteomic analysis of 144 …

Abstract The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21 th
century. However, the lack of specific drugs to prevent/treat an attack is a major need at this …

Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been
reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid …

A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
which caused a large respiratory outbreak in Wuhan, China in December 2019, is currently …